SYNCHRONOX is a multicenter cohort (retrospective then prospective) intending to include 550 patients with mid or low rectal adenocarcinoma (pMMR, T3-T4 and/or N+) and resectable synchronous liver metastases, treated upfront with at least two cycles of induction FOLFIRINOX chemotherapy. The primary objective is to determine, at 18 months, the R0 resection rate of both tumor sites (rectum and liver), while secondary objectives focus on 3 year overall and progression free survival, radiological and pathological responses, postoperative morbidity and mortality, and comparison of the different surgical strategies after FOLFIRINOX.
Adult subjects aged 18 years and older
Adenocarcinoma of the middle and/or lower rectum pMMR T3, T4, and/or N+
Resectable synchronous liver metastases
Minor under the age of 18.
Presence of extrahepatic metastases
Induction chemotherapy with FOLFIRINOX of less than 2 courses